Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan Padmanabhan Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Purpose: Dinaciclib inhibits cyclin-dependent kinases 1, 2, 5, and 9 with a better therapeutic index than flavopiridol in preclinical studies. This study assessed the activity of dinaciclib in acute leukemia both in the clinic and in vitro. Methods: Adults with relapsed/refractory acute myeloid leukemia (n = 14) and acute lymphoid leukemia (n = 6) were treated with dinaciclib 50 mg/m 2 given as a 2-h infusion every 21 days. Results: Most patients had dramatic but transient reduction in circulating blasts; however, no remissions were achieved on this schedule. The most common toxicities were gastrointestinal, fatigue, transaminitis, and clinical and laboratory manifestations of tumor lysis syndrome, including one patient who died of acute renal failure. Dinaciclib pharmacokinetics showed rapid (2 h) achievement of maximum concentration and a short elimination/distribution phase. Pharmacodynamic studies demonstrated in vivo inhibition of Mcl-1 expression and induction of PARP cleavage in patients' peripheral blood mononuclear cells 4 h after dinaciclib infusion, but the effects were lost by 24 h and did not correlate with clinical outcome. Correlative in vitro studies showed that prolonged exposures to dinaciclib, at clinically attainable concentrations, result in improved leukemia cell kill. Conclusions: While dinaciclib given as a 2-h bolus did not exhibit durable clinical activity, pharmacokinetic and pharmacodynamic data support the exploration of prolonged infusion schedules in future trials in patients with acute leukemias.

Original languageEnglish (US)
Pages (from-to)897-908
Number of pages12
JournalCancer Chemotherapy and Pharmacology
Volume72
Issue number4
DOIs
StatePublished - Oct 2013

Keywords

  • Acute leukemia
  • CDK inhibitor
  • Cyclin-dependent kinase
  • Dinaciclib
  • Mcl-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Fingerprint Dive into the research topics of 'Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias'. Together they form a unique fingerprint.

Cite this